Obatoclax Mesylate (GX15-070)

Name: Obatoclax Mesylate (GX15-070)
Brand: Selleck Chemicals
SKU: S1057
Rating: 5 (86 reviews)

For research use only.

Catalog No.S1057

86 publications

Obatoclax Mesylate (GX15-070) Chemical Structure

CAS No. 803712-79-0

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Selleck's Obatoclax Mesylate (GX15-070) has been cited by 86 publications

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cell, 2010, 20;142(4):590-600.

PubMed: 20723759 ( click the link to review the publication )

Biomaterials, 2020, 232:119709

PubMed: 31896513 ( click the link to review the publication )

Int J Mol Sci, 2020, 5;21(5) pii: E1773

PubMed: 32150830 ( click the link to review the publication )

Invest New Drugs, 2020, 4

PubMed: 32367199 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(6)

PubMed: 30875757 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30563080 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):965

PubMed: 30305055 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 10.1158/0008-5472.CAN-16-3424

PubMed: ( click the link to review the publication )

Genome Med, 2017, 9(1):40

PubMed: 28446242 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):52

PubMed: 28403890 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

FEBS J, 2017, 284(2):222-236

PubMed: 27860276 ( click the link to review the publication )

Antimicrob Agents Chemother, 2017, 61(3)

PubMed: 27993855 ( click the link to review the publication )

Electrophoresis, 2017, 10.1002/elps.201600447

PubMed: 28608427 ( click the link to review the publication )
J Exp Med, 2017, 214(6):1691-1710

PubMed: 28450382 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

Blood, 2016, 6;128(14):1834-1844

PubMed: 27465916 ( click the link to review the publication )

Nat Commun, 2016, 7:11190

PubMed: 27048913 ( click the link to review the publication )

Autophagy, 2016, 2;12(6):999-1014

PubMed: 27124102 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2016, 8(21):13218-31

PubMed: 27160664 ( click the link to review the publication )

Antiviral Res, 2016, 126:69-80

PubMed: 26738783 ( click the link to review the publication )

Cancer Cell Int, 2016, 16:27

PubMed: 27042160 ( click the link to review the publication )

Int J Oncol, 2016, 49(3):953-60

PubMed: 27572939 ( click the link to review the publication )

Oncotarget, 2016, 7(3):3520-32

PubMed: 26657288 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Oncotarget, 2016, 7(35):56253-56265

PubMed: 27494845 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26910910 ( click the link to review the publication )

Oncotarget, 2016, 8(36):60060-60079

PubMed: 28947954 ( click the link to review the publication )

Nat Chem Biol, 2015, 10.1038/nchembio.1986

PubMed: 26656090 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.05.008

PubMed: 25979228 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e2014

PubMed: 26658189 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2015, 15:97

PubMed: 26464561 ( click the link to review the publication )

Int J Oncol, 2015, 46(4):1844-8

PubMed: 25647738 ( click the link to review the publication )

BMC Cancer, 2015, 15:919

PubMed: 26585594 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )
Mol Cells, 2015, 38(3):279-84

PubMed: 25666350 ( click the link to review the publication )

Oral Dis, 2015,

PubMed: 25482163 ( click the link to review the publication )

Anticancer Drugs, 2015, 26(3):331-42

PubMed: 25521557 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26008975 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

J Pharm Pharmacol, 2015, 67(11):1575-84

PubMed: 26255619 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25749045 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(5):755-67

PubMed: 25012986 ( click the link to review the publication )

Oral Oncol, 2014, 50(2):120-7

PubMed: 24216166 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(7):3689-96

PubMed: 24752266 ( click the link to review the publication )

Biochem Pharmacol, 2014, 92(1):55-61

PubMed: 25107702 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Exp Cell Res, 2014, 322(1):217-25

PubMed: 24355809 ( click the link to review the publication )

Life Sci, 2014, 10.1016/j.lfs.2014.07.006

PubMed: 25066930 ( click the link to review the publication )

Oncol Rep, 2014, 32(6):2789-94

PubMed: 25333301 ( click the link to review the publication )

J Cell Biochem, 2014, 115(9):1624-35

PubMed: 24788582 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

Genes Cancer, 2014, 5(11-12):445-59

PubMed: 25568669 ( click the link to review the publication )

Erasmus University Rotterdam, 2014, 978-94-6259-077-9

PubMed: http://repub.eur.nl/pub/50827/ ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

Cell Death Dis, 2013,

PubMed: 23681223 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(4):448-59

PubMed: 23395885 ( click the link to review the publication )
J Immunol, 2013, 190(9):4621-6

PubMed: 23547112 ( click the link to review the publication )

Apoptosis, 2013, 18(10):1163-74

PubMed: 23887890 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 49(4):609-18

PubMed: 23668615 ( click the link to review the publication )

Exp Cell Res, 2013, 319(10):1443-50

PubMed: 23416067 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55982

PubMed: 23418490 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):3069-79

PubMed: 22525702 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e299

PubMed: 22513873 ( click the link to review the publication )

Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

BMC Cancer, 2011, 11:24

PubMed: 21247487 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features

Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Targets

Bcl-2 ^[1]
(Cell-free assay)

0.22 μM(Ki)

In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. ^[1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. ^[2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KARPAS-45	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULveFVxUUN3ME2wMlAxODB\|MUeg{txO	MkLkV2FPT0WU
SK-MEL-30	NHHUbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTETWM2OD1yLkCwNFM2PSEQvF2=	NYHGOFJHW0GQR1XS
NALM-6	NVHEXIZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TSWmlEPTB;MD6wNFA{PTZizszN	M2O3c3NCVkeHUh?=
KYSE-450	NVzBS3FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfMd2ZqUUN3ME2wMlAxODR4OTFOwG0>	NGjyNHJUSU6JRWK=
BHY	NELS[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvDb21KSzVyPUCuNFAxPjBzIN88US=>	NWjxcZlOW0GQR1XS
GR-ST	M4HueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{THOGlEPTB;MD6wNFA3PDhizszN	MnzBV2FPT0WU
786-0	M3:3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfxbGhKSzVyPUCuNFAxPzd4IN88US=>	M1PReHNCVkeHUh?=
C-33-A	NEnK[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPzTWM2OD1yLkCwNFg1QCEQvF2=	M4rXSXNCVkeHUh?=
BHT-101	NVqyb2R2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PIe2lEPTB;MD6wNFExPiEQvF2=	MV\TRW5ITVJ?
EB2	NIm3PJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELwbGhKSzVyPUCuNFAyOThizszN	MUXTRW5ITVJ?
G-361	NWnBO5I6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnocIhKSzVyPUCuNFAyOjRizszN	NF;qfVZUSU6JRWK=
KE-37	M2nKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fIdWlEPTB;MD6wNFEzQCEQvF2=	Mm\ZV2FPT0WU
MHH-PREB-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLiTWM2OD1yLkCwNVQh\|ryP	MV;TRW5ITVJ?
MCF7	NFznNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwMECxOVkh\|ryP	MojRV2FPT0WU
LOUCY	NFfIbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXKzdVE6UUN3ME2wMlAxOTd3IN88US=>	NFT6TXpUSU6JRWK=
EW-7	M4jIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjLXZhKSzVyPUCuNFAyPzVizszN	NXPMS3ppW0GQR1XS
KYSE-510	M3n0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMECyN\|Mh\|ryP	NFTjfpJUSU6JRWK=
SK-MEL-3	MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2D6XmlEPTB;MD6wNFI3PCEQvF2=	M3rqT3NCVkeHUh?=
HAL-01	NFX1dYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXD[\|dKSzVyPUCuNFAzQTdizszN	NULaVlBNW0GQR1XS
HCC2998	NYC2fGFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMECzN\|Uh\|ryP	MmfkV2FPT0WU
A375	NH3YW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwMECzOUDPxE1?	MYfTRW5ITVJ?
MZ7-mel	NF75XXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLHXIg2UUN3ME2wMlAxOzl7IN88US=>	MoG2V2FPT0WU
SH-4	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFn0dndKSzVyPUCuNFA1OTdizszN	Mmf3V2FPT0WU
HT-144	NY[xSHdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1j4O2lEPTB;MD6wNFQ{KM7:TR?=	NEjFWY1USU6JRWK=
KYSE-140	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHUfGN7UUN3ME2wMlAxPDN3IN88US=>	NVjqVolQW0GQR1XS
PSN1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrGO4hGUUN3ME2wMlAxPDZ5IN88US=>	MUjTRW5ITVJ?
COLO-679	M3Lyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3mzWWlEPTB;MD6wNFQ6QCEQvF2=	M3v1SnNCVkeHUh?=
SW620	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7Y[mh{UUN3ME2wMlAxPTFzIN88US=>	NH;JdpFUSU6JRWK=
HGC-27	NUiwPYp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHyTWM2OD1yLkCwOVI1KM7:TR?=	MlrLV2FPT0WU
IGROV-1	Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMEC2JO69VQ>?	NEfBVWdUSU6JRWK=
IGR-1	NX3aepVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TB[GlEPTB;MD6wNFYxOSEQvF2=	M3PqU3NCVkeHUh?=
EW-1	M3mzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVi1dnk2UUN3ME2wMlAxPjVzIN88US=>	Mn\hV2FPT0WU
769-P	M13pcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjHclZGUUN3ME2wMlAxPjd6IN88US=>	M4fVNHNCVkeHUh?=
HN	M3TCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljYTWM2OD1yLkCwOlc6KM7:TR?=	NH\LRYJUSU6JRWK=
SIG-M5	MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwMEC3NUDPxE1?	MUjTRW5ITVJ?
IST-MEL1	MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXIeYpKSzVyPUCuNFA5OThizszN	M1rMWXNCVkeHUh?=
ST486	MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfGTWM2OD1yLkCwPFI2KM7:TR?=	MXvTRW5ITVJ?
ES7	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkG4TWM2OD1yLkCwPFQ3KM7:TR?=	M1\XPXNCVkeHUh?=
GAK	M4fpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLvNGZJUUN3ME2wMlAxQDR6IN88US=>	MkW1V2FPT0WU
BB30-HNC	Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXvd2pKSzVyPUCuNFA5PThizszN	Moq1V2FPT0WU
IPC-298	NV[yVnZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XMcGlEPTB;MD6wNFkzPyEQvF2=	NInqS3dUSU6JRWK=
NKM-1	M4\V[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwMEC5O\|Ih\|ryP	M4qwNHNCVkeHUh?=
RKO	M2m4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMEGwOFQh\|ryP	NGj3O4ZUSU6JRWK=
ACN	MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHz4NJZKSzVyPUCuNFEyOzFizszN	MnHZV2FPT0WU
SW1417	NV3hXo9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDFeXNKSzVyPUCuNFEzOjVizszN	NHvnPYNUSU6JRWK=
SR	M1HNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M374[mlEPTB;MD6wNVI{PSEQvF2=	MVjTRW5ITVJ?
SNG-M	M3fkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTiTWM2OD1yLkCxN\|E4KM7:TR?=	Mmm4V2FPT0WU
CAL-12T	NVTyZm1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVniUWhsUUN3ME2wMlAyOzR4IN88US=>	MVzTRW5ITVJ?
HSC-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwMEGzOVUh\|ryP	M4TFUXNCVkeHUh?=
DOHH-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzXPYVlUUN3ME2wMlAyPDF{IN88US=>	MVTTRW5ITVJ?
NB69	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPXO49KSzVyPUCuNFE2PjVizszN	M33IV3NCVkeHUh?=
LC-2-ad	MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLYTWM2OD1yLkCxOVgyKM7:TR?=	MoL2V2FPT0WU
RVH-421	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEK5dFJKSzVyPUCuNFE3PzRizszN	NGjjeWdUSU6JRWK=
TGW	MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoriTWM2OD1yLkCxO\|M6KM7:TR?=	MWjTRW5ITVJ?
HCC1569	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLu[29oUUN3ME2wMlAyPzl5IN88US=>	NIfPV3FUSU6JRWK=
CAL-85-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwMEG4N\|Ih\|ryP	NYXFVmM5W0GQR1XS
RPMI-8402	NULtcolnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfUTWM2OD1yLkCxPFU5KM7:TR?=	MoGwV2FPT0WU
THP-1	NUWxSYVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG[zbIpKSzVyPUCuNFE6QThizszN	MU\TRW5ITVJ?
ONS-76	M17Ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIO0NoZKSzVyPUCuNFIxOzZizszN	NXiySG9OW0GQR1XS
A2780	MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3WTWM2OD1yLkCyNFc6KM7:TR?=	MnTqV2FPT0WU
RPMI-2650	M1TNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMEKyPVYh\|ryP	NVqwSlBxW0GQR1XS
MEL-HO	NYDIWpZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jpcGlEPTB;MD6wNlM1QCEQvF2=	NVjpdotkW0GQR1XS
MC-CAR	NG\YOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMEKzOVYh\|ryP	Ml7zV2FPT0WU
HSC-2	NGn5cHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYKwOVF3UUN3ME2wMlAzPDZ4IN88US=>	NYDLdWt7W0GQR1XS
MEL-JUSO	Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1W5TWlEPTB;MD6wNlQ4OyEQvF2=	Mmj5V2FPT0WU
CAL-62	M1PCU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwMEK2NFIh\|ryP	M2fBPXNCVkeHUh?=
DMS-273	MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMEK4OFch\|ryP	NFLtUIVUSU6JRWK=
S-117	MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3rTWM2OD1yLkCyPVA3KM7:TR?=	Mo\RV2FPT0WU
SUP-T1	NH;mOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPFTWM2OD1yLkCyPVQ6KM7:TR?=	NUDkWm52W0GQR1XS
MZ2-MEL	NUPTdm5rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUL2N4JzUUN3ME2wMlAzQTV7IN88US=>	NWLvflRDW0GQR1XS
KYSE-270	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TzWmlEPTB;MD6wNlk4PiEQvF2=	M4PGPXNCVkeHUh?=
CMK	NFHhSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMEOwNlMh\|ryP	MmjBV2FPT0WU
8505C	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzxTWM2OD1yLkCzNFQh\|ryP	NFrrUGVUSU6JRWK=
NUGC-3	NFvyVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fmcmlEPTB;MD6wN\|A1QCEQvF2=	NG\vNW5USU6JRWK=
A101D	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGW4TpVKSzVyPUCuNFMxPTVizszN	NH3Ndo9USU6JRWK=
G-401	MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwMEOwPVMh\|ryP	NFvGcYRUSU6JRWK=
OVCAR-8	NWG2SpZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwMEOxNFch\|ryP	NV\mPYlmW0GQR1XS
IMR-5	NF;VU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETQc3ZKSzVyPUCuNFMzPDRizszN	MoDvV2FPT0WU
DoTc2-4510	NGradHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvmTWM2OD1yLkCzN\|k{KM7:TR?=	M2Loc3NCVkeHUh?=
HOS	NG[4UlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7VO4dKSzVyPUCuNFM1PzNizszN	MYXTRW5ITVJ?
HEC-1	NIHFc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMEO2PEDPxE1?	NHfCO\|ZUSU6JRWK=
SW756	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLOVI9KSzVyPUCuNFM5OjFizszN	M1vxdnNCVkeHUh?=
NCI-H64	M2jFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwMEO4OFIh\|ryP	M1nYZ3NCVkeHUh?=
EW-16	MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnX0TWM2OD1yLkCzPVA6KM7:TR?=	MWLTRW5ITVJ?
CAL-51	NHPrR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{f5d2lEPTB;MD6wOFAxPSEQvF2=	MV;TRW5ITVJ?
KYSE-150	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGSxOINKSzVyPUCuNFQxOTFizszN	M4TQO3NCVkeHUh?=
SW1710	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\MO4hDUUN3ME2wMlA1ODF6IN88US=>	MUPTRW5ITVJ?
HuP-T4	M2LDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPKNpVXUUN3ME2wMlA1OTF6IN88US=>	NVmxW444W0GQR1XS
LB373-MEL-D	M2DUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7EcFNKSzVyPUCuNFQzOzJizszN	MXPTRW5ITVJ?
EW-13	NHftU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHjTWM2OD1yLkC0OFA3KM7:TR?=	NHjmN\|hUSU6JRWK=
HT-29	M3O1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXr1bmpEUUN3ME2wMlA1PDlizszN	NEC4[W9USU6JRWK=
SCC-25	M{jtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMES0PVQh\|ryP	MoKxV2FPT0WU
REH	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzRV2J[UUN3ME2wMlA1PjN3IN88US=>	MWTTRW5ITVJ?
L-363	NE\PS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\iTWxKSzVyPUCuNFQ3PzlizszN	NYewfldtW0GQR1XS
NCI-H1770	NEjCVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjZcXJKSzVyPUCuNFQ3QTdizszN	MnvhV2FPT0WU
CHL-1	NH\uU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTHPZVLUUN3ME2wMlA1QDV5IN88US=>	NIDYdlZUSU6JRWK=
ES1	M2n4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\YfVVvUUN3ME2wMlA1QDh3IN88US=>	MVvTRW5ITVJ?
SCC-15	M3G3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwMES5NFIh\|ryP	NGHjdpFUSU6JRWK=
MRK-nu-1	MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfYXWVDUUN3ME2wMlA1QTN4IN88US=>	MkDwV2FPT0WU
PF-382	NVXMeXN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXOTWM2OD1yLkC0PVM6KM7:TR?=	M1qxT3NCVkeHUh?=
COLO-680N	NVznbW1nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nJSGlEPTB;MD6wOVA1PyEQvF2=	M{DRSHNCVkeHUh?=
LK-2	MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMEWwOlMh\|ryP	M13DSnNCVkeHUh?=
NCI-H2342	NUWzPVZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMEWxNVch\|ryP	M3u4bHNCVkeHUh?=
HMV-II	M1H2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoKzTWM2OD1yLkC1NlM6KM7:TR?=	MVnTRW5ITVJ?
PC-14	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHDNmtwUUN3ME2wMlA2OjV{IN88US=>	NWL6dot{W0GQR1XS
COLO-320-HSR	NVnrPYRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfXSVhKSzVyPUCuNFUzQDlizszN	NVz0NJZtW0GQR1XS
697	NX3kblRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDNWGxKSzVyPUCuNFU{OjNizszN	M4f0THNCVkeHUh?=
NEC8	NFnVXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfubVZKSzVyPUCuNFU2QSEQvF2=	NY\UVHJnW0GQR1XS
LCLC-97TM1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHf2O5VKSzVyPUCuNFU2QTRizszN	MoTLV2FPT0WU
Daoy	M1j2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHm2V2ZKSzVyPUCuNFU3OTZizszN	M2DNbHNCVkeHUh?=
ETK-1	NXLIcoJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWj6c\|duUUN3ME2wMlA2Pjd{IN88US=>	Mn\WV2FPT0WU
A388	M4rqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMEW2PVUh\|ryP	NXu5RZdtW0GQR1XS
COLO-205	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXLTWM2OD1yLkC1O\|E3KM7:TR?=	MV3TRW5ITVJ?
SK-PN-DW	NHHLR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXIdWRpUUN3ME2wMlA2PzJ7IN88US=>	MXXTRW5ITVJ?
SF268	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojBTWM2OD1yLkC1O\|U3KM7:TR?=	M3TIUXNCVkeHUh?=
OCI-AML2	NEHwOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnEd3ZKSzVyPUCuNFU4PzdizszN	M{nr[HNCVkeHUh?=
GAMG	MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMEW4JO69VQ>?	NHrEWFlUSU6JRWK=
BCPAP	M2WyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7mfFBpUUN3ME2wMlA2QDl{IN88US=>	NGHpSYRUSU6JRWK=
BC-1	M1LQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfSb4lKSzVyPUCuNFYxOjJizszN	M3P0UnNCVkeHUh?=
IA-LM	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjlTWM2OD1yLkC2NFU{KM7:TR?=	M3O3V3NCVkeHUh?=
NCI-H1299	NVLoVGZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjjTWM2OD1yLkC2NVMh\|ryP	M{X2OXNCVkeHUh?=
COR-L23	NV;TbYN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDmbYZyUUN3ME2wMlA3OTN2IN88US=>	NYLBb3dVW0GQR1XS
KYSE-180	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjKfVRKSzVyPUCuNFYyPDJizszN	M1zNdnNCVkeHUh?=
LOXIMVI	NInRPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwME[xPFgh\|ryP	M1qyR3NCVkeHUh?=
BL-41	NW\MdYZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFz3ZlZKSzVyPUCuNFYzOTlizszN	NGnhWmZUSU6JRWK=
BL-70	M{X2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwME[zNFIh\|ryP	NEXPXnpUSU6JRWK=
NOS-1	MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M364ZWlEPTB;MD6wOlQyOSEQvF2=	MXnTRW5ITVJ?
NB13	Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXES5JvUUN3ME2wMlA3PDJzIN88US=>	MXLTRW5ITVJ?
CAL-27	M1vacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnJNnExUUN3ME2wMlA3PDZ2IN88US=>	NGGwXYVUSU6JRWK=
CA46	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvlTWM2OD1yLkC2OVM4KM7:TR?=	M4fwXHNCVkeHUh?=
SW962	M{TQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwME[1Olkh\|ryP	M{nKZ3NCVkeHUh?=
NCI-H226	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULKW4lXUUN3ME2wMlA3PjN{IN88US=>	MVLTRW5ITVJ?
KYSE-70	NWe4eVNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrhXINKSzVyPUCuNFY6PDVizszN	NXjmVWtuW0GQR1XS
Daudi	NETiVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTBwMEewPFEh\|ryP	NGO4V\|dUSU6JRWK=
SW626	NEi0VoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjWbpVMUUN3ME2wMlA4OjB2IN88US=>	NIeyfVlUSU6JRWK=
ESS-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwMEeyOFYh\|ryP	NUDG[nByW0GQR1XS
YT	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7Ub\|NKSzVyPUCuNFc{PDVizszN	M3z3OHNCVkeHUh?=
P12-ICHIKAWA	NH7sXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwMEezOFkh\|ryP	MW\TRW5ITVJ?
BxPC-3	MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vOTmlEPTB;MD6wO\|Q2QCEQvF2=	NUHPcVM{W0GQR1XS
CTV-1	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMEe1NVch\|ryP	MkH3V2FPT0WU
MLMA	M{HEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEe5Om1KSzVyPUCuNFc2OzRizszN	MYnTRW5ITVJ?
WSU-NHL	M{P4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMEe1OVQh\|ryP	MYTTRW5ITVJ?
CTB-1	NX;iR4pDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjsWGszUUN3ME2wMlA4PTh6IN88US=>	MUnTRW5ITVJ?
MMAC-SF	NFHM[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2WxXmlEPTB;MD6wO\|Y3QCEQvF2=	MUDTRW5ITVJ?
8-MG-BA	M2[2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fKNGlEPTB;MD6wO\|gxOSEQvF2=	MY\TRW5ITVJ?
NCI-H358	MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXFdVg6UUN3ME2wMlA4QDd7IN88US=>	NIfsRVVUSU6JRWK=
BFTC-905	M1vic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{m5eGlEPTB;MD6wO\|kxQSEQvF2=	MmrEV2FPT0WU
NCI-H727	NHLyeYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwMEiwOVMh\|ryP	MUTTRW5ITVJ?
CHP-212	NFzhWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEm3RZZKSzVyPUCuNFgxQTVizszN	NFyyRXBUSU6JRWK=
HOP-62	MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnf2TWM2OD1yLkC4NlQ2KM7:TR?=	MXTTRW5ITVJ?
CESS	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMEiyOlkh\|ryP	MnvDV2FPT0WU
HuCCT1	NIHxN\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMEizN\|Mh\|ryP	MlroV2FPT0WU
DEL	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoK5TWM2OD1yLkC4N\|Q4KM7:TR?=	NFS5WpdUSU6JRWK=
5637	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMEizOlch\|ryP	M2jMUXNCVkeHUh?=
RS4-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnp[4tKSzVyPUCuNFg1QTdizszN	NFfwclFUSU6JRWK=
KURAMOCHI	MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrFTWM2OD1yLkC4OVA6KM7:TR?=	NXi2Z\|VvW0GQR1XS
A427	MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwMEi1NVIh\|ryP	MX\TRW5ITVJ?
A3-KAW	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwMEi1OlYh\|ryP	Ml\uV2FPT0WU
LS-123	NWmyS5g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDSfVlKSzVyPUCuNFg4OTlizszN	M1nQdHNCVkeHUh?=
LoVo	NITiNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwMEi3NkDPxE1?	NX7CNHY4W0GQR1XS
PA-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMEi3Olkh\|ryP	NFi0cmtUSU6JRWK=
CP50-MEL-B	M2PmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEC1UYpKSzVyPUCuNFg4QTNizszN	M{j1UXNCVkeHUh?=
A431	MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jheGlEPTB;MD6wPFgxOSEQvF2=	MV\TRW5ITVJ?
HCT-116	NHTseFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fXdmlEPTB;MD6wPFgxOiEQvF2=	NED6XFJUSU6JRWK=
A4-Fuk	M3\jN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrZUmlvUUN3ME2wMlA5QTR5IN88US=>	M1y0WHNCVkeHUh?=
RPMI-6666	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rVcmlEPTB;MD6wPFk3PyEQvF2=	NI\CO\|NUSU6JRWK=
Calu-6	MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMEmwNlkh\|ryP	NILWepdUSU6JRWK=
KMOE-2	NX61VJZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmn3TWM2OD1yLkC5NFM6KM7:TR?=	M{jINHNCVkeHUh?=
A704	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jwdWlEPTB;MD6wPVE2KM7:TR?=	NV3DSmYyW0GQR1XS
HO-1-N-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{naOmlEPTB;MD6wPVI1QSEQvF2=	M17JPHNCVkeHUh?=
NCI-H2122	NFrZU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnZTWM2OD1yLkC5N\|c5KM7:TR?=	NX3DTZNNW0GQR1XS
U-698-M	NF\5U21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;wNpBoUUN3ME2wMlA6PDB7IN88US=>	MXrTRW5ITVJ?
IST-SL2	MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jQSWlEPTB;MD6wPVQ3QCEQvF2=	M2r5TXNCVkeHUh?=
TE-10	NH3xNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF71bIdKSzVyPUCuNFk2QDRizszN	MXnTRW5ITVJ?
PANC-03-27	MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwMEm2O\|Eh\|ryP	MnnqV2FPT0WU
KYSE-410	M4PuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDKTWM2OD1yLkC5O\|k4KM7:TR?=	M{LZfXNCVkeHUh?=
TE-8	NGjWNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnT3TWM2OD1yLkC5PFg2KM7:TR?=	NH\TblVUSU6JRWK=
MN-60	M1zo[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2Px[mlEPTB;MD6wPVg6PyEQvF2=	M1PwTHNCVkeHUh?=
NCI-H460	NYLsbIV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnjeVU2UUN3ME2wMlExODlizszN	NYD5SGUzW0GQR1XS
LB771-HNC	MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPDTWM2OD1yLkGwNlU2KM7:TR?=	M4TFfnNCVkeHUh?=
ES4	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rIRmlEPTB;MD6xNFI3PCEQvF2=	MYTTRW5ITVJ?
HUTU-80	MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwMUCzOlUh\|ryP	M2\RRXNCVkeHUh?=
647-V	NILCUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPLTZdxUUN3ME2wMlExPDB6IN88US=>	MkjuV2FPT0WU
HTC-C3	MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDRc5Y5UUN3ME2wMlExPDN{IN88US=>	NXTsOmhDW0GQR1XS
NTERA-S-cl-D1	NVrXUpJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInzbHJKSzVyPUCuNVA1PDhizszN	NX:3[VQ5W0GQR1XS
A2058	Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jGW2lEPTB;MD6xNFY2PSEQvF2=	M1zVdXNCVkeHUh?=
MZ1-PC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rVb2lEPTB;MD6xNFg{KM7:TR?=	M{TTT3NCVkeHUh?=
J82	NHvGUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Xuc2lEPTB;MD6xNFg5PCEQvF2=	NU\LdoVrW0GQR1XS
ARH-77	NWq0N5NjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXex[4FlUUN3ME2wMlEyKM7:TR?=	M1vMbXNCVkeHUh?=
Ca9-22	NGDEVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfFTWM2OD1yLkGxNVI5KM7:TR?=	MWHTRW5ITVJ?
NCI-H1648	NX7PfFY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrPTZhKSzVyPUCuNVEzQDZizszN	NIK4d5hUSU6JRWK=
MC116	Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XRNWlEPTB;MD6xNVM{PyEQvF2=	NFfrcFdUSU6JRWK=
EoL-1-cell	MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMUG0Olch\|ryP	NGT5T3FUSU6JRWK=
PANC-10-05	NYiwcHFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmOwTWM2OD1yLkGxOFkyKM7:TR?=	MUHTRW5ITVJ?
SF539	NVixRWFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml65TWM2OD1yLkGxOlE3KM7:TR?=	NEOyOmRUSU6JRWK=
ES8	M37oO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHqTWM2OD1yLkGxOlM{KM7:TR?=	NF\xUlBUSU6JRWK=
NCI-H810	NG[zWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwMUG2OlQh\|ryP	NY[yRndmW0GQR1XS
J-RT3-T3-5	M1TYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvhWWdrUUN3ME2wMlEyPzVizszN	NEHXe5dUSU6JRWK=
NY	NF7Y[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIqzNVZKSzVyPUCuNVE5OTdizszN	M{HCT3NCVkeHUh?=
NCI-SNU-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPMTWM2OD1yLkGyNVQ5KM7:TR?=	M33EVnNCVkeHUh?=
EFM-19	NFjuZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37kemlEPTB;MD6xNlM4PCEQvF2=	NVyxeVdwW0GQR1XS
HCC1806	NF[yfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYj4PZV4UUN3ME2wMlEzOzh\|IN88US=>	MoK3V2FPT0WU
HCE-T	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjNZXdKSzVyPUCuNVI2OzFizszN	MYPTRW5ITVJ?
HT-1376	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnme2JJUUN3ME2wMlEzPjZ6IN88US=>	MknGV2FPT0WU
BE-13	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPUXFdLUUN3ME2wMlEzQDZ4IN88US=>	M1\n[nNCVkeHUh?=
NCI-H520	NFvWUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjOWoF1UUN3ME2wMlEzQDZ5IN88US=>	MUnTRW5ITVJ?
SK-MES-1	M1L0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMUK5NVMh\|ryP	NGC1Z\|RUSU6JRWK=
SNU-423	MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDkZopHUUN3ME2wMlEzQTF2IN88US=>	M2jNfHNCVkeHUh?=
Ramos-2G6-4C10	NWrvbYJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HOdmlEPTB;MD6xNlkyPiEQvF2=	MoLVV2FPT0WU
EW-18	M2nrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzxfW1kUUN3ME2wMlE{ODJ4IN88US=>	NFrE[IdUSU6JRWK=
NCI-H2087	M2n6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMUOwNlch\|ryP	MVfTRW5ITVJ?
COLO-792	NH\mb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGn5UpBKSzVyPUCuNVMyPjVizszN	MmfYV2FPT0WU
QIMR-WIL	NFK5UmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;qbWFKSzVyPUCuNVMzOjNizszN	NGLkXnhUSU6JRWK=
ACHN	MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\wWGpPUUN3ME2wMlE{OjR5IN88US=>	MVrTRW5ITVJ?
RPMI-8866	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTqR2Y3UUN3ME2wMlE{OjZzIN88US=>	NVS3OHhIW0GQR1XS
SK-LU-1	M3;1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3j6fWlEPTB;MD6xN\|Q1QSEQvF2=	NVTjV\|I{W0GQR1XS
SK-UT-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXK3[JRzUUN3ME2wMlE{PjJ6IN88US=>	MlXiV2FPT0WU
MFE-296	M1n5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMUO4OlQh\|ryP	NGDiWZNUSU6JRWK=
RD	NGnxTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjvXlRKSzVyPUCuNVM6QTdizszN	NHnuNHVUSU6JRWK=
LS-411N	NW\mfHBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHydZhKSzVyPUCuNVQzQTVizszN	MWjTRW5ITVJ?
NCI-H747	M{TPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXXPHYyUUN3ME2wMlE1OyEQvF2=	NWHLdmJkW0GQR1XS
ES6	NWD0[HB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMUSzOkDPxE1?	M2jaSHNCVkeHUh?=
TE-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPrTWM2OD1yLkG0OFA4KM7:TR?=	MVvTRW5ITVJ?
SJSA-1	Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwMUS3NFch\|ryP	MlW0V2FPT0WU
NCI-H1355	M3yzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLWeFJKSzVyPUCuNVUzQTNizszN	M{DueHNCVkeHUh?=
HEL	MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfYSnVKSzVyPUCuNVU1PDdizszN	NX3EVllnW0GQR1XS
639-V	M13XSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrqWppKSzVyPUCuNVU2QTZizszN	NU\4[HNRW0GQR1XS
AN3-CA	MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37oVmlEPTB;MD6xOVY{QSEQvF2=	NF3ZWlJUSU6JRWK=
SK-MEL-2	Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fzVWlEPTB;MD6xOVY3QCEQvF2=	NEO4VoRUSU6JRWK=
SW872	NXnWN3FsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTBwMU[wOFIh\|ryP	Mkn3V2FPT0WU
DU-4475	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwMU[xOlIh\|ryP	NED6T2pUSU6JRWK=
YKG-1	M1rFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTOTWM2OD1yLkG2Nlc{KM7:TR?=	MXzTRW5ITVJ?
GT3TKB	Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnOVGZKSzVyPUCuNVYzQDNizszN	NHHYfIZUSU6JRWK=
GB-1	NGnOXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVm0[oVkUUN3ME2wMlE3PDJ2IN88US=>	MUPTRW5ITVJ?
KARPAS-422	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\ITWM2OD1yLkG2OVc1KM7:TR?=	MYDTRW5ITVJ?
ATN-1	M3XQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrITWM2OD1yLkG2OlU3KM7:TR?=	NYDGeZQyW0GQR1XS
HLE	MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nwbmlEPTB;MD6xOlg4PyEQvF2=	NFrTR4xUSU6JRWK=
D-542MG	M1TrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHruTIRKSzVyPUCuNVY6QDZizszN	MlHVV2FPT0WU
EB-3	M3TOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYL2SnJVUUN3ME2wMlE4OzFizszN	MkPGV2FPT0WU
HCC1143	NY\zdWNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYq5dHBNUUN3ME2wMlE4Ozl4IN88US=>	MlS4V2FPT0WU
DJM-1	NGrHc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLR[nNKSzVyPUCuNVc1PTFizszN	MmTkV2FPT0WU
BT-474	NXHLfZVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HmTmlEPTB;MD6xO\|Q5QSEQvF2=	NISzN2pUSU6JRWK=
BB65-RCC	M2DhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYexbG1vUUN3ME2wMlE4PTR3IN88US=>	MkK1V2FPT0WU
NCI-H292	Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLkTWM2OD1yLkG3OlAyKM7:TR?=	M3\WXHNCVkeHUh?=
MKN28	NHXSZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[0PXZvUUN3ME2wMlE4PjV\|IN88US=>	NEHqfW5USU6JRWK=
TK10	NXvqSJlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH32NWFKSzVyPUCuNVc4ODJizszN	M1nTWnNCVkeHUh?=
TYK-nu	NELPfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDjWmlNUUN3ME2wMlE4QTR7IN88US=>	NWHhWJZwW0GQR1XS
8305C	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;lTWM2OD1yLkG3PVcyKM7:TR?=	MojnV2FPT0WU
MV-4-11	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwMUe5O\|ch\|ryP	NXH4UW5RW0GQR1XS
NCI-H522	MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwMUiwPVQh\|ryP	MYjTRW5ITVJ?
Hs-578-T	M4jFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTQdHJMUUN3ME2wMlE5Ojl{IN88US=>	MmPyV2FPT0WU
LCLC-103H	Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMUi1Nlch\|ryP	MlnDV2FPT0WU
MHH-ES-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmWzTWM2OD1yLkG4OlI6KM7:TR?=	NUfKb5d5W0GQR1XS
NCI-H441	Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjDTWM2OD1yLkG5NVQ5KM7:TR?=	Moi4V2FPT0WU
AM-38	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwMUmyNlUh\|ryP	M3v4UXNCVkeHUh?=
SW1783	NF3SbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3vR\|l3UUN3ME2wMlE6OzB3IN88US=>	MXHTRW5ITVJ?
SK-HEP-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXT0U5BrUUN3ME2wMlE6PjN5IN88US=>	MnflV2FPT0WU
OAW-28	NFLtVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrtfmVKSzVyPUCuNlAyPzhizszN	NIraN2NUSU6JRWK=
TE-15	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3n0OWlEPTB;MD6yNFI2OiEQvF2=	NXnEdotbW0GQR1XS
HCE-4	NVnOemI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzTPZFKSzVyPUCuNlAzQDRizszN	MmexV2FPT0WU
JiyoyeP-2003	NW[0NGVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMkCzN\|Yh\|ryP	MmH6V2FPT0WU
OVCAR-4	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HaVGlEPTB;MD6yNFYzQCEQvF2=	NInIUY1USU6JRWK=
SNU-449	MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrpeHdKSzVyPUCuNlA4QTdizszN	NEnrT\|NUSU6JRWK=
SBC-5	NUe0V2k6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrpVYxKSzVyPUCuNlEzOTVizszN	NUTaSopYW0GQR1XS
T84	Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwMkGyOFgh\|ryP	M2nLZXNCVkeHUh?=
LP-1	M4WxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\IRndIUUN3ME2wMlIyOzB{IN88US=>	M1jGeXNCVkeHUh?=
MG-63	M37uOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TMXWlEPTB;MD6yNVM5OiEQvF2=	MnX5V2FPT0WU
OAW-42	MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDS[olIUUN3ME2wMlIyPDd6IN88US=>	MoX4V2FPT0WU
L-540	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMkG1PVgh\|ryP	MXfTRW5ITVJ?
RH-1	NX\tO2JtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Xsc2lEPTB;MD6yNlI1OiEQvF2=	MlTCV2FPT0WU
HCT-15	MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fn[GlEPTB;MD6yNlQ5PCEQvF2=	NYTHRZNZW0GQR1XS
OCUB-M	MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HydWlEPTB;MD6yNlQ5QCEQvF2=	NILYNlZUSU6JRWK=
GP5d	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3m4SmlEPTB;MD6yNlUzQCEQvF2=	MUjTRW5ITVJ?
NCI-H2030	NUjTUFRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkOxTWM2OD1yLkKyO\|M1KM7:TR?=	NIDDco1USU6JRWK=
ML-2	NFTLR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHoRYpwUUN3ME2wMlIzQDh7IN88US=>	M{j5Z3NCVkeHUh?=
CAL-39	M2XTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nIZWlEPTB;MD6yNlk{PiEQvF2=	NGCzfXhUSU6JRWK=
MIA-PaCa-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwMkOyPFch\|ryP	NF;qeZBUSU6JRWK=
TE-9	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrCTWM2OD1yLkKzN\|Ih\|ryP	NFHje5RUSU6JRWK=
LB2518-MEL	M12zVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjhdo1UUUN3ME2wMlI{Ozd{IN88US=>	NYXqOWk5W0GQR1XS
DB	NWf6Sm1CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMkO0N\|gh\|ryP	MYXTRW5ITVJ?
NCI-H596	MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHT1SlFKSzVyPUCuNlM2PzFizszN	MkDyV2FPT0WU
SW1990	M4fzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\p[YlKSzVyPUCuNlM6PDZizszN	NGTDcYhUSU6JRWK=
P30-OHK	M{HqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDoZZA{UUN3ME2wMlI1ODVizszN	M3vOOHNCVkeHUh?=
ALL-PO	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3uTWM2OD1yLkK0NVY6KM7:TR?=	NXPYfWlpW0GQR1XS
Saos-2	MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrGToZtUUN3ME2wMlI1PTdzIN88US=>	MkLBV2FPT0WU
MFH-ino	NV[yOGk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfsb4JVUUN3ME2wMlI1Pjl{IN88US=>	MlqwV2FPT0WU
OE33	NH7HeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zJZ2lEPTB;MD6yOVEyKM7:TR?=	NXf2cXZQW0GQR1XS
Calu-3	MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMkWyPVch\|ryP	M{X6SHNCVkeHUh?=
HT	M3G2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMkW2NlEh\|ryP	MWPTRW5ITVJ?
LXF-289	MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIG3bmdKSzVyPUCuNlU6QDRizszN	MYPTRW5ITVJ?
KGN	NHHQU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwMk[wPFkh\|ryP	NFnmeHlUSU6JRWK=
NCI-H1417	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DzSWlEPTB;MD6yOlUzPCEQvF2=	MV\TRW5ITVJ?
SF126	NVTxTYFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfnTYVKSzVyPUCuNlc{ODJizszN	NYXUUGxpW0GQR1XS
SAS	NEHud4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\GdWhVUUN3ME2wMlI4OzB6IN88US=>	NH;a[2RUSU6JRWK=
22RV1	Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PIVmlEPTB;MD6yO\|M4QCEQvF2=	MXzTRW5ITVJ?
GI-1	NFLae\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYWzfI1VUUN3ME2wMlI4PDh5IN88US=>	M4H2WXNCVkeHUh?=
ES3	M1Kzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITTfoFKSzVyPUCuNlc4PjNizszN	MXfTRW5ITVJ?
NB1	M3WxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwMke4O\|Yh\|ryP	M2e0bXNCVkeHUh?=
NCI-H650	NVnHVnhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrKS3lvUUN3ME2wMlI5OzB{IN88US=>	NUO2eo8yW0GQR1XS
IST-MES1	MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnpO3VYUUN3ME2wMlI5PTV2IN88US=>	M4rONXNCVkeHUh?=
UM-UC-3	NH7xOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfHTWM2OD1yLkK5NVQh\|ryP	NH7hT3lUSU6JRWK=
CAL-120	Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXkeVQ1UUN3ME2wMlI6PjNzIN88US=>	MWDTRW5ITVJ?
UACC-62	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXzSlhKSzVyPUCuN\|AzPDFizszN	M1zzWHNCVkeHUh?=
TE-11	M2nLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fUUmlEPTB;MD6zNFI1QSEQvF2=	MXrTRW5ITVJ?
MKN1	M2f5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\ySVdKSzVyPUCuN\|A{PiEQvF2=	M37NbnNCVkeHUh?=
KS-1	NFTZbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml:xTWM2OD1yLkOwOVI3KM7:TR?=	MojSV2FPT0WU
GCIY	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml6xTWM2OD1yLkOxNFAzKM7:TR?=	MmToV2FPT0WU
OVCAR-5	NXvyNItJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwM{GxNFYh\|ryP	MmPSV2FPT0WU
U-266	MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\MTWM2OD1yLkOxNVQ4KM7:TR?=	MVHTRW5ITVJ?
Calu-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXIZVRMUUN3ME2wMlMyOjh7IN88US=>	NWey[o93W0GQR1XS
SK-LMS-1	NILVNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIO5eGRKSzVyPUCuN\|E1OjlizszN	M3v0N3NCVkeHUh?=
COLO-741	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwM{G2NVQh\|ryP	M{TOfHNCVkeHUh?=
RPMI-8226	NV\NeGVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnKTWM2OD1yLkOxOlQyKM7:TR?=	NVrm[Y56W0GQR1XS
KM12	M3m1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\wVJVKSzVyPUCuN\|E5OyEQvF2=	NVXuNXN6W0GQR1XS
NMC-G1	M3TNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzjTWM2OD1yLkOxPFYh\|ryP	M3P6b3NCVkeHUh?=
SJRH30	NH;YOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HHR2lEPTB;MD6zNlA2OiEQvF2=	NGGzOZhUSU6JRWK=
COR-L105	M4GwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XvNWlEPTB;MD6zNlIyQCEQvF2=	NVz1b4xEW0GQR1XS
IM-9	M3nLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\jTWM2OD1yLkOzNFIyKM7:TR?=	NVi2XpdrW0GQR1XS
TE-12	NXHBZWFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUf2fJA3UUN3ME2wMlM{OzF5IN88US=>	NVi2XnZwW0GQR1XS
KG-1	NEHZbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwM{O0N\|Ih\|ryP	MoHYV2FPT0WU
U251	M13jSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwM{O0OVYh\|ryP	M2H1b3NCVkeHUh?=
EFO-27	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TMWWlEPTB;MD6zN\|k2OSEQvF2=	NWOxdHA5W0GQR1XS
EW-24	MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnz3TWM2OD1yLkOzPVg1KM7:TR?=	NGLT[ZpUSU6JRWK=
SF295	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwM{O5PVkh\|ryP	MmSzV2FPT0WU
MC-IXC	NVexU4hVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDjPGtWUUN3ME2wMlM1PSEQvF2=	M3;I[nNCVkeHUh?=
NCI-H2405	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2q3[GlEPTB;MD6zOFc{OiEQvF2=	Mn\tV2FPT0WU
NCI-H2009	M1m5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\WO2VKSzVyPUCuN\|Q4OzlizszN	NV;VWHdDW0GQR1XS
LB1047-RCC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXhVWRsUUN3ME2wMlM2QDF3IN88US=>	NIfnUotUSU6JRWK=
KNS-81-FD	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXDXI9mUUN3ME2wMlM3PjZ5IN88US=>	MV;TRW5ITVJ?
HOP-92	NFTpTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjLO2JKSzVyPUCuN\|Y5OyEQvF2=	NX;zbXBQW0GQR1XS
L-428	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLTPJdFUUN3ME2wMlM4ODF4IN88US=>	NUDET\|BtW0GQR1XS
C3A	NGXaXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;QenhKSzVyPUCuN\|c{PzlizszN	NHS1[HdUSU6JRWK=
NCI-H1792	M2\j[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInISIpKSzVyPUCuN\|c3PTVizszN	NXG4cIVSW0GQR1XS
HuH-7	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHLXlNFUUN3ME2wMlM4QTFizszN	NIPRSXRUSU6JRWK=
AGS	NXfWdYRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3v5UGlEPTB;MD6zPFY{QCEQvF2=	NUfGfYlYW0GQR1XS
HT-1197	Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfqTWM2OD1yLkO5OFYh\|ryP	NGLtZmlUSU6JRWK=
CGTH-W-1	NHf2VXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILMOpZKSzVyPUCuN\|k6OTNizszN	MXzTRW5ITVJ?
KNS-42	M{nrZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwNECwOFUh\|ryP	Mn\wV2FPT0WU
HuO-3N1	NXXkZXR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3RT4tKSzVyPUCuOFAxPTVizszN	NVTifIk6W0GQR1XS
VMRC-RCZ	MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{e4NGlEPTB;MD60NFMxOyEQvF2=	NWnpdVNCW0GQR1XS
SW954	NV31dmdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLaTWM2OD1yLkSwN\|M2KM7:TR?=	M3rD[XNCVkeHUh?=
MES-SA	NV6ySpBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm[1TWM2OD1yLkSwOVA2KM7:TR?=	NFK1bWdUSU6JRWK=
Ca-Ski	NVmySXZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:xRY5KSzVyPUCuOFA2OjRizszN	M2P1enNCVkeHUh?=
SW13	NYrYOJA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrKNG9KSzVyPUCuOFA3OjZizszN	NVLJUYJjW0GQR1XS
NCI-H1437	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1T3OGlEPTB;MD60NFgxPSEQvF2=	NIDveW5USU6JRWK=
U-118-MG	NI\2[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoKyTWM2OD1yLkSwPVA1KM7:TR?=	MWPTRW5ITVJ?
NCI-H1734	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwNEKwNVMh\|ryP	M2PXdXNCVkeHUh?=
HDLM-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWKwUYlEUUN3ME2wMlQzODN\|IN88US=>	NYHufZBOW0GQR1XS
AU565	M375fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLuVHVKSzVyPUCuOFI1PjhizszN	MWDTRW5ITVJ?
FADU	M1jM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInDR5hKSzVyPUCuOFI3PDlizszN	NWnJemZxW0GQR1XS
OS-RC-2	Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrWSINKSzVyPUCuOFMxQDNizszN	NH;TToJUSU6JRWK=
CAMA-1	NHnsVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLubIxFUUN3ME2wMlQ{PjJ4IN88US=>	NWfoUIxIW0GQR1XS
MONO-MAC-6	NF:zbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzWXo1KSzVyPUCuOFM5PDlizszN	NE[wco9USU6JRWK=
LB831-BLC	M1fscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwNESzO\|Eh\|ryP	M{fIVnNCVkeHUh?=
SW982	NX70NXZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXLTWM2OD1yLkS0OVI5KM7:TR?=	MWXTRW5ITVJ?
SCC-3	M4\6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NET4RXdKSzVyPUCuOFQ2PzlizszN	NWHiflZ7W0GQR1XS
C32	MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGiyTpNKSzVyPUCuOFUzOjlizszN	MkWxV2FPT0WU
BFTC-909	M3THVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzHdXAzUUN3ME2wMlQ2Ojl7IN88US=>	MVnTRW5ITVJ?
MEG-01	NWTHNGZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVL2VIVEUUN3ME2wMlQ2Ozd\|IN88US=>	MoHIV2FPT0WU
M14	M{K5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fEPWlEPTB;MD60OVk4QSEQvF2=	MlntV2FPT0WU
MPP-89	NETmem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTSR4hPUUN3ME2wMlQ3OjV4IN88US=>	M3fFT3NCVkeHUh?=
HCC1937	NEDNTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnvd5VKSzVyPUCuOFY{QDRizszN	NHjlcFVUSU6JRWK=
SW837	NYrBPWtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LXfWlEPTB;MD60OlczOiEQvF2=	NWHXfldtW0GQR1XS
DU-145	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXEW2pyUUN3ME2wMlQ3PzJ7IN88US=>	MYLTRW5ITVJ?
LB996-RCC	M3nReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELTZWJKSzVyPUCuOFcxPTRizszN	M1fWfXNCVkeHUh?=
C8166	NYPHOHN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\SVWlEPTB;MD60O\|Qh\|ryP	M1n4NnNCVkeHUh?=
MOLT-4	MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwNEe3N\|Qh\|ryP	NXPIe4dxW0GQR1XS
DMS-53	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnYTWM2OD1yLkS3PFA6KM7:TR?=	NYrZdmw2W0GQR1XS
TE-5	MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrSTFF{UUN3ME2wMlQ5OzB3IN88US=>	NUDqNZhHW0GQR1XS
KYSE-520	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTBwNEizOFMh\|ryP	M{LmWnNCVkeHUh?=
Detroit562	MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4n6dWlEPTB;MD60PFg3KM7:TR?=	M3:zdnNCVkeHUh?=
SIMA	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXqTWM2OD1yLkS5OFE4KM7:TR?=	NXfXUWJTW0GQR1XS
NCI-H1651	Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HYXmlEPTB;MD60PVY4KM7:TR?=	NGiyfYRUSU6JRWK=
HCC1599	NFfyeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnRTWM2OD1yLkS5PVU2KM7:TR?=	MmLrV2FPT0WU
ABC-1	NUjNTFZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXG0c5NTUUN3ME2wMlUxPDl4IN88US=>	M1m4PHNCVkeHUh?=
CAL-33	NHHGbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkD4TWM2OD1yLkWwPFQ1KM7:TR?=	NGOxc2xUSU6JRWK=
OPM-2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHReYF6UUN3ME2wMlUxQTN5IN88US=>	NWqyW5g2W0GQR1XS
RPMI-7951	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEf3PJFKSzVyPUCuOVA6PTdizszN	M4PhPHNCVkeHUh?=
HT-1080	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojITWM2OD1yLkWxNVE6KM7:TR?=	NHzIZYxUSU6JRWK=
LC4-1	Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwNUG0NFMh\|ryP	MkjqV2FPT0WU
OVCAR-3	NFLSTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUGxdpNkUUN3ME2wMlUyPTdizszN	M2nwW3NCVkeHUh?=
CAPAN-1	M3vuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fGOmlEPTB;MD61NlI5QCEQvF2=	M336dHNCVkeHUh?=
SK-OV-3	MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTsTWM2OD1yLkWyOFM1KM7:TR?=	M3HvZnNCVkeHUh?=
HuP-T3	NXzHO4NlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwNUK4Nlch\|ryP	MVfTRW5ITVJ?
NCI-H838	NV7UdFBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjSfIlKSzVyPUCuOVI5PDlizszN	NG\0OItUSU6JRWK=
K5	NXPx[ot6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfMTWM2OD1yLkWzNlAyKM7:TR?=	NVnFTGNmW0GQR1XS
CAL-72	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwNUOzPFch\|ryP	MYPTRW5ITVJ?
NH-12	M3:xO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2naemlEPTB;MD61N\|k2QSEQvF2=	NI\rVnpUSU6JRWK=
SNB75	NVXwelc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzE[2hnUUN3ME2wMlU2PzNizszN	NETNcpNUSU6JRWK=
BPH-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTBwNU[zOFQh\|ryP	NX;sV4w{W0GQR1XS
NOMO-1	M2m3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnrVI5KSzVyPUCuOVY{PzJizszN	MYDTRW5ITVJ?
G-402	M4\pdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTGd25KSzVyPUCuOVY1QTlizszN	NIn5RXdUSU6JRWK=
NCI-H2052	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrPWooxUUN3ME2wMlU3PzRzIN88US=>	Mnv3V2FPT0WU
RCM-1	NWTaVHlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwNUexOlYh\|ryP	M4XrZnNCVkeHUh?=
COR-L279	NUPrNWJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnW3TWM2OD1yLkW3NVg2KM7:TR?=	Mly5V2FPT0WU
A253	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXoTWM2OD1yLkW3OVI2KM7:TR?=	M37zWHNCVkeHUh?=
SK-MM-2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwNUe2O\|kh\|ryP	MWjTRW5ITVJ?
NCI-H1703	MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\wT4VyUUN3ME2wMlU6PDJ5IN88US=>	NEXhb4ZUSU6JRWK=
UACC-257	MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHNflBKSzVyPUCuOVk1QDdizszN	MYTTRW5ITVJ?
KALS-1	NGT4Om1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwNkCwNVEh\|ryP	M{XKZnNCVkeHUh?=
ES5	M4SwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjsdVFbUUN3ME2wMlYxPDhizszN	MXzTRW5ITVJ?
MHH-CALL-2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXlTWM2OD1yLk[wPFg5KM7:TR?=	NX[xdmZbW0GQR1XS
ChaGo-K-1	NX;GfJRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwNkGyNlkh\|ryP	NGLSVnJUSU6JRWK=
TGBC1TKB	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwNkG5PEDPxE1?	NULHVJJwW0GQR1XS
KU-19-19	M2ToXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPVWHVKSzVyPUCuOlQ2QDZizszN	NVfzR4VNW0GQR1XS
COLO-684	NVHVTFZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfITWM2OD1yLk[1OlEyKM7:TR?=	MlnnV2FPT0WU
LS-1034	MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwNkW4NVkh\|ryP	NHfVWVRUSU6JRWK=
RT-112	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjBSFVKSzVyPUCuOlY2QDdizszN	NXPUR5NtW0GQR1XS
Capan-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTpUXg5UUN3ME2wMlY3PjJ{IN88US=>	NIS2[ZNUSU6JRWK=
HSC-4	M1rnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvlcmlOUUN3ME2wMlY3Pjl6IN88US=>	NGPqOJhUSU6JRWK=
COLO-824	M1XKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;LTWM2OD1yLk[3PFI{KM7:TR?=	NYG2c\|VGW0GQR1XS
NCI-H2170	NFLmeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPCW2p6UUN3ME2wMlY5OjV6IN88US=>	M{T6fnNCVkeHUh?=
GDM-1	NYrhWVg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXG5THdOUUN3ME2wMlY5PDl2IN88US=>	M3u5NXNCVkeHUh?=
KP-4	M1eyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwNkm1O\|Mh\|ryP	MYTTRW5ITVJ?
VA-ES-BJ	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7LW5BKSzVyPUCuOlk6QDZizszN	MlXJV2FPT0WU
KM-H2	NELoS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwN{CwPVEh\|ryP	Mn76V2FPT0WU
HH	NYLKbGVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHJTWM2OD1yLkewOlYzKM7:TR?=	MV7TRW5ITVJ?
DK-MG	NEfUO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwN{GwNVYh\|ryP	MkHCV2FPT0WU
VM-CUB-1	M3LVWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUe1dYtWUUN3ME2wMlcyOjV7IN88US=>	NV\GPHpKW0GQR1XS
COLO-829	NUnle213T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPJV5EzUUN3ME2wMlcyQTh3IN88US=>	MX7TRW5ITVJ?
OMC-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwN{KxNFQh\|ryP	M1G3UHNCVkeHUh?=
NB12	M{nu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnPfmdKSzVyPUCuO\|I2ODRizszN	Ml3CV2FPT0WU
NCI-H28	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\o[4dqUUN3ME2wMlc1ODh\|IN88US=>	MnvHV2FPT0WU
A673	NXLpdoM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33SdWlEPTB;MD63OVE4PyEQvF2=	M4T0eXNCVkeHUh?=
LB2241-RCC	M4[zZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vscGlEPTB;MD63OlA5PyEQvF2=	M4T3dHNCVkeHUh?=
CCRF-CEM	MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fBXWlEPTB;MD63O\|A2OiEQvF2=	M1fuW3NCVkeHUh?=
NCI-H510A	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zo[2lEPTB;MD63O\|E5PiEQvF2=	NYG0fIlEW0GQR1XS
SW48	M4DLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrhTWM2OD1yLke3N\|M{KM7:TR?=	M2C5R3NCVkeHUh?=
NCI-H2081	NW\EOmh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwN{ixOFch\|ryP	MXLTRW5ITVJ?
RMG-I	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwN{iyNVIh\|ryP	MVHTRW5ITVJ?
LU-99A	M1SzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2e3bGlEPTB;MD63PFQyOyEQvF2=	MnjlV2FPT0WU
KP-N-YS	MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\QTWM2OD1yLke4PVIyKM7:TR?=	NHK2dZNUSU6JRWK=
MDA-MB-231	M3\3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVraWYQ3UUN3ME2wMlgxOTNzIN88US=>	MU\TRW5ITVJ?
U031	M4rBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3BZo9{UUN3ME2wMlgyPDJ\|IN88US=>	MUnTRW5ITVJ?
EVSA-T	NGXrVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwOEG2O\|Ih\|ryP	M320PXNCVkeHUh?=
MDA-MB-157	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rlWmlEPTB;MD64NlI4OSEQvF2=	MXLTRW5ITVJ?
EHEB	NHLxPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\HTWM2OD1yLkiyNlc3KM7:TR?=	NGfOeXFUSU6JRWK=
KINGS-1	M{nubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwOEK1OVUh\|ryP	MXzTRW5ITVJ?
23132-87	M1fkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfDdnVKSzVyPUCuPFI5PDNizszN	M3vzVXNCVkeHUh?=
EFO-21	MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnrTWM2OD1yLki0NFg6KM7:TR?=	MmrsV2FPT0WU
DOK	Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnOwTWM2OD1yLki0PEDPxE1?	Mn3tV2FPT0WU
NCI-H2171	MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwOES5OkDPxE1?	NVzCNo1uW0GQR1XS
NCI-SNU-5	M2XuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHoeW9sUUN3ME2wMlg2PTdizszN	NVzzTm51W0GQR1XS
SK-N-DZ	NEnjNWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjSTWM2OD1yLki1PVQ{KM7:TR?=	NHzFdoxUSU6JRWK=
SNU-C2B	Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1r0UmlEPTB;MD64OlgxOSEQvF2=	MVvTRW5ITVJ?
CP66-MEL	M{HU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;VRnNsUUN3ME2wMlg4OTFizszN	MkDzV2FPT0WU
SN12C	Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LIbGlEPTB;MD64PFY{PyEQvF2=	NWTQNGFNW0GQR1XS
A172	MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvxZXNKSzVyPUCuPFg3QThizszN	MoLaV2FPT0WU
NCI-H2347	NWryOWFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HQdWlEPTB;MD64PFc2OyEQvF2=	NHzQd5hUSU6JRWK=
NCI-H2228	Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwOEmzN\|kh\|ryP	Mke1V2FPT0WU
SNU-387	M{LyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\rZmlEPTB;MD65NFI3PCEQvF2=	NUnZWGJMW0GQR1XS
SK-MEL-24	M{WxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfidmdKSzVyPUCuPVE{PDRizszN	NH\4OVZUSU6JRWK=
MDA-MB-468	M1XsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3SwfWlEPTB;MD65NVc{KM7:TR?=	NI\xdoVUSU6JRWK=
NCI-H1694	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1T4WGlEPTB;MD65NVg4PiEQvF2=	M4\PPXNCVkeHUh?=
CCF-STTG1	M4DPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjoTWM2OD1yLkmyOlM4KM7:TR?=	MWPTRW5ITVJ?
K052	M4HRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjlTWM2OD1yLkm0NFQ4KM7:TR?=	MlPQV2FPT0WU
NCI-H446	NVL1O5lwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELa[JFKSzVyPUCuPVUxOSEQvF2=	M1\Z[HNCVkeHUh?=
MFE-280	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUeyXHE1UUN3ME2wMlk3OjlzIN88US=>	M4\qcnNCVkeHUh?=
KU812	NFf2UGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH64e5RKSzVyPUCuPVk{QDlizszN	NH;2S21USU6JRWK=
MDA-MB-361	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfUNpdKSzVyPUCuPVk4PzdizszN	NX7xVYhoW0GQR1XS
Raji	M{jLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXTTWM2OD1zLkCyNlY4KM7:TR?=	NGTDO2JUSU6JRWK=
TE-6	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTFwMEO1OlYh\|ryP	M{XhXHNCVkeHUh?=
CAL-148	NY[0cY42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPuTZB3UUN3ME2xMlA1PDR\|IN88US=>	MYnTRW5ITVJ?
NCI-H1963	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DvVWlEPTB;MT6wOFU2OyEQvF2=	MlLVV2FPT0WU
SK-N-AS	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvOOFFKSzVyPUGuNFQ3QDVizszN	M4DUSXNCVkeHUh?=
RERF-LC-MS	M1\YfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTFwME[zOFkh\|ryP	MWPTRW5ITVJ?
BEN	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvITWM2OD1zLkC3NVM4KM7:TR?=	M4jRfnNCVkeHUh?=
CAS-1	NXTVdIt7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDuZXVKSzVyPUGuNFkyOjNizszN	MlHWV2FPT0WU
SW780	NXjqXpNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTFwMEmxPFEh\|ryP	MXzTRW5ITVJ?
LU-65	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTFwMEm0NUDPxE1?	MmPIV2FPT0WU
D-283MED	M1:zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\4NGN5UUN3ME2xMlEzOjd{IN88US=>	MYnTRW5ITVJ?
HCC2157	MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrsTVlKSzVyPUGuNVM3PDJizszN	M{P4W3NCVkeHUh?=
RCC10RGB	M3HrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jUT2lEPTB;MT6xOFAxPiEQvF2=	M4j2OHNCVkeHUh?=
PLC-PRF-5	NIH4epBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTCXpRtUUN3ME2xMlE2OjJ7IN88US=>	MkniV2FPT0WU
H4	NYXRUm97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;ETWM2OD1zLkG1OFM6KM7:TR?=	MmfPV2FPT0WU
TUR	NWjPbZhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTFwMUW3OVIh\|ryP	NWP0TpRnW0GQR1XS
NCI-H2141	M3nNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGH2TJJKSzVyPUGuNVg6PDZizszN	NYH3XVdKW0GQR1XS
PFSK-1	M1n3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnJW2xKSzVyPUGuNlA2OzJizszN	NGezS3FUSU6JRWK=
SK-MEL-28	MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3r5SmlEPTB;MT6yN\|IzOSEQvF2=	M1mxenNCVkeHUh?=
SCC-9	Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTFwMkO2OlUh\|ryP	MYrTRW5ITVJ?
T47D	NVHDSZI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYm4cWRnUUN3ME2xMlI{Pjl4IN88US=>	MlHMV2FPT0WU
TCCSUP	NI\pOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTFwMkWwNlkh\|ryP	NIXmd4ZUSU6JRWK=
SU-DHL-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTFwMkWxNVgh\|ryP	MkTXV2FPT0WU
HL-60	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmK4TWM2OD1zLkK1OVg5KM7:TR?=	MXnTRW5ITVJ?
NCI-H1436	NWXDfnhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLQdZF3UUN3ME2xMlI3OTR7IN88US=>	M1vBZXNCVkeHUh?=
DMS-114	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTFwMk[2N\|Ih\|ryP	MlPjV2FPT0WU
BOKU	NEDpNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTFwMkiwPVUh\|ryP	NFm2d2NUSU6JRWK=
MS-1	NUfNSFUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXnTWM2OD1zLkK5NFY6KM7:TR?=	NHvOWXFUSU6JRWK=
NCI-H661	MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnR[WtFUUN3ME2xMlMxPDd6IN88US=>	Mlv3V2FPT0WU
HT-3	M{DZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHi2WlVKSzVyPUGuN\|A2OjlizszN	MV;TRW5ITVJ?
CAL-54	MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkS0TWM2OD1zLkOwO\|I2KM7:TR?=	NXLwXHdpW0GQR1XS
SW1463	NGe4eZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jxWGlEPTB;MT6zNVg4OiEQvF2=	MlXrV2FPT0WU
COLO-668	NXXzb4V4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4i4XWlEPTB;MT6zN\|A2PiEQvF2=	NWTvSWJGW0GQR1XS
PANC-08-13	NYPFSnd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTFwM{O4NFMh\|ryP	MWnTRW5ITVJ?
BB49-HNC	M{TyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2K1OGlEPTB;MT6zOFAyKM7:TR?=	Mo\FV2FPT0WU
M059J	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PkSmlEPTB;MT6zOVg{OiEQvF2=	NFfDbXlUSU6JRWK=
NCCIT	M37SR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofRTWM2OD1zLkO3PVg5KM7:TR?=	NUjBUZRNW0GQR1XS
LN-405	M4XiPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHxZ2VKSzVyPUGuN\|kzPjRizszN	MUPTRW5ITVJ?
UMC-11	NVnrVYZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTFwM{m5PVYh\|ryP	M13nenNCVkeHUh?=
NB5	NVvZXlltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrlWmEzUUN3ME2xMlQyOjJ5IN88US=>	MV;TRW5ITVJ?
TE-441-T	MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvFfI9mUUN3ME2xMlQzQDF5IN88US=>	M4\KWXNCVkeHUh?=
ME-180	NH7Pb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7TeJBKSzVyPUGuOFQ{QTJizszN	MUfTRW5ITVJ?
HCC70	M1fCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nYZWlEPTB;MT60OlA6PiEQvF2=	M37vNnNCVkeHUh?=
no-10	NX3tVmlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTFwNE[xPFEh\|ryP	MUXTRW5ITVJ?
JEG-3	M4rkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXIcm9KSzVyPUGuOVAyOzJizszN	M2rocnNCVkeHUh?=
no-11	NHrJcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETZbHlKSzVyPUGuOVA5QDJizszN	NFr1[nJUSU6JRWK=
CHP-126	Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPqdGJKSzVyPUGuOVY3QTFizszN	M{DSVXNCVkeHUh?=
EGI-1	M1fnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTlVY5SUUN3ME2xMlU5ODJ3IN88US=>	MWfTRW5ITVJ?
D-392MG	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDveIR2UUN3ME2xMlU6PjNizszN	NXXmcFZYW0GQR1XS
RT4	NGWwZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTFwNUm2N\|ch\|ryP	NHO4[FlUSU6JRWK=
A204	MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfhOVBRUUN3ME2xMlU6QDBzIN88US=>	MlfBV2FPT0WU
NCI-H1304	M2PyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7iTWM2OD1zLk[zOVkyKM7:TR?=	NIn1PY5USU6JRWK=
Becker	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTBTWM2OD1zLk[0NlQyKM7:TR?=	M2i0UHNCVkeHUh?=
OE19	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTFwNkW1NVgh\|ryP	NYjobFdOW0GQR1XS
EKVX	MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIOw[YVKSzVyPUGuOlU3OThizszN	MX7TRW5ITVJ?
KLE	M3HRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XQbWlEPTB;MT62OVcyPCEQvF2=	MYLTRW5ITVJ?
K-562	NVLwSVZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGGybVBKSzVyPUGuOlcxOzdizszN	MVrTRW5ITVJ?
MDA-MB-175-VII	M1jtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTFwNki5PVch\|ryP	NUPVS25vW0GQR1XS
NCI-H716	MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLVe4JyUUN3ME2xMlY6OzB2IN88US=>	MXzTRW5ITVJ?
Caov-3	NHK3R2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTsTWM2OD1zLk[5OFE{KM7:TR?=	MXLTRW5ITVJ?
HCC1187	NHPuVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXyTWl1UUN3ME2xMlcxPTR3IN88US=>	MU\TRW5ITVJ?
CAKI-1	NILjVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIm2VlRKSzVyPUGuO\|IzQTJizszN	M4e3WHNCVkeHUh?=
MOLT-16	MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzUd3NwUUN3ME2xMlc{OzB5IN88US=>	MnPFV2FPT0WU
PC-3	Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTFwN{WwPEDPxE1?	NUf0ZoE1W0GQR1XS
DV-90	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkP4TWM2OD1zLke1OVg2KM7:TR?=	NUnMNoVzW0GQR1XS
RXF393	NYnUUI9FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvpTVNKSzVyPUGuO\|czQTRizszN	MkizV2FPT0WU
SK-NEP-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XmRWlEPTB;MT64NlM{QSEQvF2=	NF7hepRUSU6JRWK=
HCC1419	M2\Nb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPuTWM2OD1zLkiyOlkzKM7:TR?=	M2H6S3NCVkeHUh?=
BV-173	NVe2VG9IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXwc5pKSzVyPUGuPFI6QTVizszN	NInmdmRUSU6JRWK=
MKN7	NFzBVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTFwOEmyNkDPxE1?	M3ni[3NCVkeHUh?=
LAN-6	NHfVWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTFwOEm1OVMh\|ryP	NH3ZS4NUSU6JRWK=
Mo-T	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDjTWM2OD1zLkmwNFM6KM7:TR?=	NVHnbnF[W0GQR1XS
HCC1395	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTDeGgzUUN3ME2xMlkzQDZ\|IN88US=>	MVHTRW5ITVJ?
HC-1	NGez[\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTFwOUO0O{DPxE1?	MVnTRW5ITVJ?
HPAF-II	MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\GbWNKSzVyPUGuPVQ1OThizszN	M4XGOHNCVkeHUh?=
CPC-N	NYfuTHBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\vTWM2OD1zLkm4NFAzKM7:TR?=	MXXTRW5ITVJ?
MKN45	MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TaVmlEPTB;MT65PVEyQSEQvF2=	NVThd2Z3W0GQR1XS
NCI-H1693	NU\iPFNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXTRopVUUN3ME2yMlAxPDN\|IN88US=>	M2rDbXNCVkeHUh?=
SHP-77	M{KyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPnTWM2OD1{LkCwOVM{KM7:TR?=	Ml;jV2FPT0WU
NCI-H1522	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXSxTJRsUUN3ME2yMlAyPzJ2IN88US=>	MoPwV2FPT0WU
SW1573	NIXsSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHsRo9KSzVyPUKuNFIzKM7:TR?=	MXnTRW5ITVJ?
DBTRG-05MG	M3rLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTJwME[wPFch\|ryP	M2PIVnNCVkeHUh?=
SCC-4	NIfBRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzYTWM2OD1{LkG0N\|Eh\|ryP	MVvTRW5ITVJ?
DMS-153	NVS4WVV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zBZ2lEPTB;Mj6xOlY3QCEQvF2=	NFLtfpdUSU6JRWK=
MDA-MB-415	NIjjUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fKTWlEPTB;Mj6xO\|UzKM7:TR?=	NFTQflZUSU6JRWK=
NCI-H2126	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HW[2lEPTB;Mj6yNlg5QCEQvF2=	NV65dYdxW0GQR1XS
MDA-MB-453	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn2xTWM2OD1{LkKzN\|Ih\|ryP	NI\abFRUSU6JRWK=
U-87-MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlflTWM2OD1{LkK4OVkzKM7:TR?=	MmjoV2FPT0WU
LNCaP-Clone-FGC	NVv3cVE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnBeG1zUUN3ME2yMlMxOTB{IN88US=>	NF6zRpBUSU6JRWK=
NCI-H1581	NWjmPHBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTJwM{KxNFUh\|ryP	M4PhbnNCVkeHUh?=
BC-3	NH:yPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PhdGlEPTB;Mj6zOlUxQSEQvF2=	NIjDcW9USU6JRWK=
HCC38	MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnn3TWM2OD1{LkO4OFQ4KM7:TR?=	NIXZSXRUSU6JRWK=
HCC2218	NVjKd45jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljDTWM2OD1{LkSwPFA6KM7:TR?=	NFzCTJFUSU6JRWK=
RO82-W-1	NUX5S3pGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF74OnJKSzVyPUKuOFEzPSEQvF2=	NFTMVJpUSU6JRWK=
C2BBe1	MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTJwNEG1O\|gh\|ryP	NIjVeYRUSU6JRWK=
LAMA-84	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDOTWM2OD1{LkW3N\|Y5KM7:TR?=	M1ywdHNCVkeHUh?=
GMS-10	NUjX[2gyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPve\|l1UUN3ME2yMlU4PjFzIN88US=>	NXP6VY5zW0GQR1XS
GCT	NU\oOGZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{ewZWlEPTB;Mj61PFY6PCEQvF2=	NEPtfYpUSU6JRWK=
SK-CO-1	NUnwOJdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HJ[GlEPTB;Mj62NVY3KM7:TR?=	MV;TRW5ITVJ?
NCI-H526	NEfqSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml[yTWM2OD1{Lk[zOFUh\|ryP	NHzMZZpUSU6JRWK=
SW1088	NEf0W41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDXTWM2OD1{Lke3PFM6KM7:TR?=	M4n2O3NCVkeHUh?=
HT55	NUjofFd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHHTI85UUN3ME2yMlc5Pjl3IN88US=>	MWLTRW5ITVJ?
NB10	M3P3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3FTWM2OD1{LkixO\|Q5KM7:TR?=	M3ztWnNCVkeHUh?=
UACC-893	NUjwe404T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33Ve2lEPTB;Mj64OVc1QSEQvF2=	MkH0V2FPT0WU
NCI-H1618	MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jlbWlEPTB;Mj64PFE2OyEQvF2=	NH\VfJBUSU6JRWK=
NCI-H1092	NVHVR4xIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2P3O2lEPTB;Mz6wO\|gyOiEQvF2=	MoPNV2FPT0WU
SBC-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLGUVdKSzVyPUOuNFg2PTNizszN	MonGV2FPT0WU
NCI-H1623	M{[z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTNwMEmzOEDPxE1?	Mk\QV2FPT0WU
SiHa	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTNwMUG5O\|ch\|ryP	NWjEU2RCW0GQR1XS
D-263MG	NVzUdGZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTNwMUS3PFgh\|ryP	MUnTRW5ITVJ?
NCI-H1573	NWTTUnJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTNwMUm2OFEh\|ryP	M2nxWnNCVkeHUh?=
NCI-H82	M3LpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTNwM{S0N\|kh\|ryP	MWjTRW5ITVJ?
NCI-H2196	NVLYfGY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUO3SFhKUUN3ME2zMlM2ODB6IN88US=>	MXHTRW5ITVJ?
MFM-223	M{LDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIKyV21KSzVyPUOuN\|c{PTFizszN	MYjTRW5ITVJ?
COLO-678	M{foZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHhTWM2OD1\|LkO4NVg3KM7:TR?=	NUnJTGpUW0GQR1XS
EW-3	NFXJeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIf5TJZKSzVyPUOuOFA6PSEQvF2=	MV7TRW5ITVJ?
MHH-NB-11	NESxW\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnj1TWM2OD1\|LkS0NFY6KM7:TR?=	NXH6TYN3W0GQR1XS
EM-2	NHLIZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PKS2lEPTB;Mz62N\|k5KM7:TR?=	Mn;2V2FPT0WU
FTC-133	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPCcIhKSzVyPUOuOlU1PThizszN	M3\WPXNCVkeHUh?=
NCI-H209	NWjQOHlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLCbJhKSzVyPUOuOlc3PTNizszN	MnnFV2FPT0WU
TGBC24TKB	NFy1VZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXVUldKSzVyPUOuOlg{PTVizszN	MnK0V2FPT0WU
LC-1F	NYP3SXJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTNwN{G3OlQh\|ryP	MWXTRW5ITVJ?
C-4-II	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXzVmxKSzVyPUOuO\|U3PDNizszN	MXnTRW5ITVJ?
NCI-H1650	NGDzVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTNwN{i0OVUh\|ryP	NUHLTmc5W0GQR1XS
JVM-2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37MUWlEPTB;Mz65N\|Y{QSEQvF2=	NVTmOG1EW0GQR1XS
CaR-1	NUHPcoRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;2TWM2OD1\|Lkm3OlE4KM7:TR?=	NYLlcmFjW0GQR1XS
MDA-MB-134-VI	MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDHTWM2OD12LkCyPVUzKM7:TR?=	NVrjT3JnW0GQR1XS
NCI-H719	M{XoR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTnTWM2OD12LkG1N\|g5KM7:TR?=	NXnKbVdWW0GQR1XS
GOTO	MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjE[FlPUUN3ME20MlI6PzB3IN88US=>	NYr5boF3W0GQR1XS
NCI-N87	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XDbWlEPTB;ND6zPFgzOSEQvF2=	Ml7lV2FPT0WU
NB6	M4nsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLHTWM2OD12LkSyOVA6KM7:TR?=	NFvrU4lUSU6JRWK=
DSH1	NIr4eI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGKyeVlKSzVyPUSuOFcyOTZizszN	M4\QPHNCVkeHUh?=
BT-20	NYmybVBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfXcFVKSzVyPUSuOFkxODJizszN	NF\GSVBUSU6JRWK=
NCI-H1882	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvITWM2OD12LkWwOVch\|ryP	M2LjXHNCVkeHUh?=
WM-115	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPxTWM2OD12LkWwPFgyKM7:TR?=	NUnrVm5OW0GQR1XS
SKG-IIIa	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYm4THJKUUN3ME20MlY4PzdizszN	MnTEV2FPT0WU
NCI-H69	NYfJd3hrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnFSo5KSzVyPUSuO\|AzPzVizszN	M4XCcnNCVkeHUh?=
MSTO-211H	NV3oUWt[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTRwOEO1OlUh\|ryP	NHXQWJVUSU6JRWK=
Mewo	NXzEdmw3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml31TWM2OD12Lkm2N\|E{KM7:TR?=	M2XMNHNCVkeHUh?=
GI-ME-N	NH;l[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XzU2lEPTB;NT6wNFUxQSEQvF2=	MYfTRW5ITVJ?
T98G	MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PsZWlEPTB;NT6wOlUxQCEQvF2=	M{jzfHNCVkeHUh?=
ECC4	M4GxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfITWM2OD13LkC5N\|czKM7:TR?=	MofHV2FPT0WU
EW-11	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrTfnFKSzVyPUWuNVgxQTlizszN	Ml\SV2FPT0WU
COLO-800	NXnae4VqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmG2TWM2OD13LkG5N\|Q6KM7:TR?=	NYfBWnZRW0GQR1XS
NCI-H1755	MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTVwMkOwNlch\|ryP	MmCzV2FPT0WU
KMS-12-PE	NX:0ToRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnu2TWM2OD13LkO1NFg2KM7:TR?=	MXjTRW5ITVJ?
HCC1954	NGHLSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvxTWM2OD13Lki1PVcyKM7:TR?=	MnvpV2FPT0WU
NCI-H187	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUX2RXdEUUN3ME21MlkzQTh7IN88US=>	NWD0UGRPW0GQR1XS
LU-165	NVzGT5VTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPLTWM2OD13Lkm5NFAzKM7:TR?=	Moj0V2FPT0WU
YAPC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2GxRWlEPTB;NT65PVA3QCEQvF2=	MkPnV2FPT0WU
LU-139	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1T5XmlEPTB;Nj6wPFM3QCEQvF2=	MVjTRW5ITVJ?
D-502MG	NI\ZfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3EcpBCUUN3ME22MlMzODR5IN88US=>	M1m0PXNCVkeHUh?=
IST-SL1	NIHF[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTZwNUO5OFgh\|ryP	MlTrV2FPT0WU
DG-75	NXPEU2lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnYTWM2OD14Lki4O\|g3KM7:TR?=	NITVZnhUSU6JRWK=
NCI-H1155	M2PF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTZwOUW1PFEh\|ryP	M{K5PXNCVkeHUh?=
EFE-184	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPpTWM2OD15LkOxOlk2KM7:TR?=	M3PIeXNCVkeHUh?=
AsPC-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIf6WotKSzVyPUeuOFg5ODdizszN	M3nES3NCVkeHUh?=
SW948	NGjLVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLF[JpKSzVyPUeuOVg{QTVizszN	NIjCeldUSU6JRWK=
NCI-H524	MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTlwNUi2Nlgh\|ryP	M4\mNXNCVkeHUh?=
KOSC-2	M3Prbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;iZmlEPTB;OT62Nlg{PCEQvF2=	MmDtV2FPT0WU
T-24	M2G1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTlwOUS0NVUh\|ryP	NFvjRnNUSU6JRWK=
NCI-H748	MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTzZ4Q2UUN3ME2xNE43Ozl5IN88US=>	MXHTRW5ITVJ?
NCI-H23	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLtWVBKSzVyPUGwMlY1PDJizszN	M12yfHNCVkeHUh?=
UACC-812	M3WybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTKNpVKSzVyPUGxMlcyPyEQvF2=	NF7o[FBUSU6JRWK=
SCLC-21H	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfjTWM2OD1zMj6xOVUyKM7:TR?=	MVvTRW5ITVJ?
NCI-SNU-16	MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTF\|LkGyOVgh\|ryP	MXHTRW5ITVJ?
HD-MY-Z	M1XmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDWb4tGUUN3ME2xOE43OzZ\|IN88US=>	MYDTRW5ITVJ?
SK-N-FI	NVe0Z4U2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLrSodwUUN3ME2xOE45QTF{IN88US=>	M4rNbnNCVkeHUh?=
LB647-SCLC	NFLPO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrPcWp5UUN3ME2xOU44OTl3IN88US=>	M122[HNCVkeHUh?=
NCI-H345	NHP0XGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnP4TWM2OD1zNz6zOFMh\|ryP	MoH4V2FPT0WU
NCI-H1563	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnWfWNKSzVyPUG4Mlc3ODFizszN	NYXzSJpzW0GQR1XS
RL	NHS4TGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\kTWM2OD1{MT6yOlU3KM7:TR?=	Ml7HV2FPT0WU
KY821	NGHiZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Lsb2lEPTB;MkKuNFU2OyEQvF2=	M2DFXXNCVkeHUh?=
JVM-3	NEHFXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDGcVByUUN3ME2yOU4xPDF\|IN88US=>	M4DyNHNCVkeHUh?=
NCI-H1793	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHmT\|hKSzVyPUK4MlU1QTlizszN	NWTQSFQ5W0GQR1XS
LU-134-A	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTNyLkKwN\|ch\|ryP	MlLWV2FPT0WU
NCI-H1395	M1jtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjyTWM2OD1\|Mj6yOFMyKM7:TR?=	NHXsSnVUSU6JRWK=
NCI-H1993	NUDCfHh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvXTWM2OD1\|Mj64NlE5KM7:TR?=	MoKxV2FPT0WU
P31-FUJ	NXm4OXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HUUWlEPTB;M{OuOFg6QSEQvF2=	MX3TRW5ITVJ?
LS-513	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWC4UYxmUUN3ME2zOU45QDd7IN88US=>	NVXTNFNCW0GQR1XS
SK-MEL-1	Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfuTWM2OD12MD6zOFk6KM7:TR?=	NFfnOHZUSU6JRWK=
SW684	M3jzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjWfWs1UUN3ME20N{46PjZzIN88US=>	NV33dGNMW0GQR1XS
COR-L88	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzCUYVKSzVyPUS0MlA3PjVizszN	NH7MWmVUSU6JRWK=
NCI-H889	MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfaTWM2OD12NT6wNFg4KM7:TR?=	MoG3V2FPT0WU
TALL-1	MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnSN28yUUN3ME20Ok4yOTl7IN88US=>	MXXTRW5ITVJ?
KARPAS-299	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nwfWlEPTB;NEeuNVk6OyEQvF2=	MkTmV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cyclin D1 / p27 Kip1 ; PubMed: 28382170 Theranostics Western blotting showed that Obatoclax impacted cell cycle distribution through lowering cyclin D1 in K1 cells but in BCPAP cells, it impacted expression of p27 Kip1 rather than cyclin D1. p-Cyclin D1 ; PubMed: 28035994 Int J Mol Sci Cell line-dependent effect of obatoclax on cyclin D1 T286 phosphorylation. HCT116, HT-29, and LoVo cells were subject to 24 h-treatment with obatoclax (200 nM), followed by immunoblotting to evaluate the levels of threonine 286 (T286)-phosphorylated cyclin D1 (p-Cyclin D1) at indicated time points. α-Tubulin levels served as equal loading control; p-GSK3β / GSK3β / p-ERK / ERK / p-p38 / p38; PubMed: 28035994 Int J Mol Sci Obatoclax inhibits GSK3β but activates p38 (MAPK), while barely affecting ERK1/2 activity in HT-29 cells. HT-29 cells were exposed to 200 nM of obatoclax for 24 h. The status of activation of GSK3β, ERK1/2, and p38(MAPK) at indicated time points was determined by immunoblotting for corresponding phosphorylation. Specifically, serine 9-phosphorylation of GSK3β (p-GSK3β) reveals inhibition of GSK3β activity, whereas dual phosphorylation at threonine 202/tyrosine 204 of ERK1/2 (p-ERK1/2) and threonine 180/tyrosine 182 of p38 MAPK (p-p38) indicate activation of ERK1/2 and p38(MAPK), respectively. α-Tubulin levels served as equal loading control;	28382170 28035994
Growth inhibition assay	Cell proliferation ; PubMed: 28035994 Int J Mol Sci Obatoclax inhibits colorectal cancer cell proliferation. Human colorectal carcinoma cell lines HCT116, HT-29, and LoVo cells were treated with obatoclax (0, 50, 100, 200 nM) for 24, 48, and 72 h. The numbers of cells at each time point were counted using a Neubauer chamber. Data were presented as the percentage relative to the drug-untreated control. Cell viability; PubMed: 21368880 Cell Death Dis H727 NSCLC cells are resistant to obatoclax. H727 and H1975 NSCLC cells were treated with obatoclax at the indicated doses for 48 (left) or 72 h (right), and the viability of cells determined by ViaLight assay. The EC50 values of cells at 48 h were; H1975 267 nM; H727 3.2 μM. The EC50 values of cells at 72 h were; H1975 66 nM; H727 621 nM. Data are expressed as mean±S.D.	28035994 21368880

In vivo

Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Bcl-2 Binding affinity calculation: A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. ^[4] As a control in determining the reliability of the calculation, predicted binding affinities K_i) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:^[2]	- Collapse Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) Concentrations: ~10 μM Incubation Time: 48-72 hours Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 10⁴ per well for HMCLs or 5~10 × 10³ for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used. Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg Administration: Administered intravenously (tail vein) once a day (Only for Reference)

References

[4] Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.

- Collapse

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.73 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Molecular Weight	413.49
Formula	C₂₀H₁₉N₃O.CH₄O₃S
CAS No.	803712-79-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=CC(=C(N1)C=C2C(=CC(=C3C=C4C=CC=CC4=N3)N2)OC)C.CS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00438178	Completed	Drug: Obatoclax mesylate (GX15-070MS)	Hematological Malignancies	Gemin X\|Teva Pharmaceutical Industries	October 2005	Phase 1
NCT00600964	Completed	Drug: GX15-070MS	Chronic Lymphocytic Leukemia	Gemin X\|Teva Pharmaceutical Industries	September 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Pan Bcl-2 Inhibitor

ABT-737 : Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax (BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. AT-101 simultaneously triggers apoptosis and a cytoprotective type of autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)